Trademark Overview
On Wednesday, September 3, 2025, a trademark application was filed for CAYMNIRV with the United States Patent and Trademark Office. The USPTO has given the CAYMNIRV trademark a serial number of 99371423. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Friday, January 16, 2026. This trademark is owned by Glaxo Group Limited. The CAYMNIRV trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives